Clinical Trial Search

Primary: Percentage of Participants With Severe Bleeding Episodes Who Demonstrated Response to TAK-672 Therapy at 24 Hours After the Initiation of Treatment — 100 percentage of…

Primary: Change From Baseline in Weekly Urticaria Score (UAS7) at Week 12 (Scenario 1 With UAS7 as Primary Efficacy Endpoint) — -20.02; -13.79 Scores on a scale — p=<0.001

Primary: Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks — 0.56; 1.08 Exacerbation per participant per year — p=<0.001

Primary: Change From Baseline to Visit 16 in PCL-5 Total Score — -14.92 score on a scale

Primary: Primary Event (Acute Hematologic or GI Toxicity) — 55; 46 Participants

Primary: Change From Baseline in Body Weight (Percentage [%]) — -12.5; -3.6 Percentage change — p=<0.0001

Primary: Ranked Endpoints : 1. Sum of Pain Intensity Differences at 6 Hours (SPID0-6h) — 8955.4; 8458.0; 5290.7 score on a scale — p=0.0031

Primary: C-peptide Area Under the Curve (AUC) — 0.57; 0.60; 0.66; 0.60 (pmol/ml)*minutes — p=0.89

Primary: Percentage of Participants With Grade ≥3 AEs — 49.7 percentage of participants

Primary: Number of Subjects' Eyes That Show < 0.50 D Myopia Progression (SER, Spherical Equivalent Refraction) at the Month 36 Visit — 79; 106; 61 participants' eyes

Primary: HAMD-17 — 16.4; 16.2 score on a scale

Primary: Regional Cerebral Blood Flow Using Arterial Spin-labeling MRI — 55.7; 54.5 mL/g/min — p=0.17

Primary: Concentrations at the End of the Dosing Interval (Ctau) of CAB LA 400 mg Following Administration CAB LA + RPV LA — 2.759; 2.670; 2.607; 2.632 microgram per milliliter…

Primary: Maximum Drug Concentration (Cmax) of Setmelanotide After QD Administration in the Run-in Period — 29.4; 44.8; 59.9 nanograms per milliliter (ng/mL)

Primary: Number of Participants With Adverse Events — 9; 9; 8 Participants